• Xvivo Perfusion held its Q3 2026 earnings call on October 22 with CEO Christoffer Rosenblad and CFO Kristoffer Nordstrom.
• Net sales reached SEK 253 million, representing 32% organic growth; EBITDA rose to SEK 52 million from SEK 36 million.
• Management targets a US Heart Assist Transport launch in late 2027, followed by Liver Assist in early 2028, subject to regulatory clearance.
• Sales force investments for the US heart and liver launches are expected to cause a slight margin decline in the second half of 2027.
• Kidney growth could reach around 30% in 2027, but component shortages will prevent the business from meeting full market demand.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xvivo Perfusion AB published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.